FALIPHARMA
ActiveSummary
FALIPHARMA has been active since 1982 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €325k and a net result of €48k. Equity is growing by ~5.7% per year across the filed fiscal years. Its solvency ranks better than 58% of 10359 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
81
/ 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability77▲+10
Solvency69▲+3
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €25k at 30 days acceptable
Liquidity ample (current ratio 3.99 against 5.19 in 2024; short-term debt: 18.2% and cash: 33.2% of total assets), but 55.6% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
44.4%
Return on assets
6.5%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-07-2026, 7 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
7 d early
2024
19 d late
2023
21 d late
2022
18 d early
2021
25 d early
2020
9 d late
2019
14 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€48k▲ 46.2%
2024 · €33k
2018: €34k
2019: €4k
2020: €7k
2021: €5k
2022: €8k
2023: €19k
2024: €33k
2018 → 2025
Working capital
€399k▲ 6.4%
2024 · €375k
2018: €312k
2019: €323k
2020: €345k
2021: €318k
2022: €371k
2023: €332k
2024: €375k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€217k-€224k▲ 3.2%€243k▲ 8.4%€277k▲ 14.1%€325k▲ 17.2%
Operating result€21k-€28k▲ 35.8%€39k▲ 37.5%€58k▲ 47.2%€80k▲ 38.3%
Net result€5k-€8k▲ 50.2%€19k▲ 146%€33k▲ 73.3%€48k▲ 46.2%
Result per fiscal year
Operating resultNet result
The operating result has risen four years in a row; 2025 is 38% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €732k
Fixed assets
€199k ▼ 8.1%
Current assets
€532k ▲ 14.6%
Equity and liabilities €732k
Equity
€325k ▲ 17.2%
Debt
€407k ▲ 0.6%
Debt's share of the balance-sheet total falls from 59.4% to 55.6%. Equity and debt are higher.
Key figures and ratios
EBITDA
€103k▲
2024 · €80k
Cash flow
€71k▲
2024 · €55k
Current ratio
3.99▼
2024 · 5.19
Quick ratio
2.54▼
2024 · 3.07
Debt to equity
1.25▼
2024 · 1.46
ROE
14.7%▲
2024 · 11.8%
ROA
6.5%▲
2024 · 4.8%
Interest coverage
6.60▲
2024 · 5.07
Debt ≤ 1 year
€134k▲
2024 · €90k
Debt > 1 year
€254k▼
2024 · €305k
Income taxes
€18k▲
2024 · €11k
Staff costs
€162k▲
2024 · €158k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 51 lines
Balance sheet
Code20242025
Assets
Total assets20/58€682k€732k▲
Fixed assets21/28€217k€199k▼
Tangible fixed assets22/27€211k€193k▼
Land and buildings22€142k€129k▼
Plant, machinery and equipment23€67k€59k▼
Furniture and vehicles24€1k€5k▲
Financial fixed assets28€6k€6k=
Current assets29/58€465k€532k▲
Stocks and contracts in progress3€189k€194k▲
Stocks30/36€189k€194k▲
Amounts receivable within one year40/41€69k€89k▲
Trade receivables40€69k€85k▲
Other amounts receivable41€0€4k▲
Current investments50/53-€7
Cash at bank and in hand54/58€202k€243k▲
Deferred charges and accrued income490/1€4k€6k▲
Equity and liabilities
Total equity and liabilities10/49€682k€732k▲
Equity10/15€277k€325k▲
Contributions10/11€19k€19k=
Reserves13€189k€189k=
Distributable reserves133€189k€189k=
Profit (loss) carried forward14€69k€117k▲
Amounts payable17/49€405k€407k▲
Amounts payable after more than one year17€305k€254k▼
Financial debts170/4€110k€101k▼
Other amounts payable178/9€195k€153k▼
Amounts payable within one year42/48€90k€134k▲
Current portion of amounts payable after more than one year42€9k€51k▲
Trade debts44€34k€37k▲
Suppliers440/4€34k€37k▲
Taxes, remuneration and social security45€36k€34k▼
Taxes450/3€13k€12k▼
Remuneration and social security454/9€22k€23k▲
Other amounts payable47/48€11k€11k▲
Accrued charges and deferred income492/3€10k€20k▲
Income statement
Code20242025
Remuneration, social security and pensions62€158k€162k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€23k€23k▲
Other operating charges640/8€5k€5k▼
Gross operating margin9900€243k€270k▲
Operating profit (loss)9901€58k€80k▲
Financial income75/76B€2k€2k▲
Recurring financial income75€2k€2k▲
Financial charges65/66B€16k€16k▼
Recurring financial charges65€16k€16k▼
Profit (loss) for the period before taxes9903€44k€66k▲
Income taxes67/77€11k€18k▲
Profit (loss) for the period9904€33k€48k▲
Profit (loss) for the period to be appropriated9905€33k€48k▲
Appropriation of the result
Profit (loss) to be appropriated9906€69k€117k▲
Profit (loss) brought forward from the previous period14P€37k€69k▲
Social balance
Average headcount (FTE)90873.03.0=
The notes to these accounts (15 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
04-08
State Gazette act
Permanent representative: Céline RUTHRegistered-office move3 facts ▸
State Gazette act
Permanent representative: Céline RUTH
Registered-office move3 facts ▸
- General meeting, 05/05/2026
- Registered-office move, Rue J.J. Merlot(FAL) 3A - 5060 Sambreville
- Permanent representative, Céline RUTH
24-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Highest result since 2018net €48k ▲46.2%
Operating result €80k, net result €48k, both a record.
19-08
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 19 days late
2024
21-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 21 days late
2023
13-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
06-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
09-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 9 days late
2020
14-08
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 14 days late
2019
31-12
Financial
Weakest financial yearnet €4k ▼87.7%
Net result drops to €4k, the lowest in the series; recovery starts the following year.
16-09
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 47 days late
2018
29-08
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 29 days late
2017
26-07
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 1. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sambreville · 2 establishment units since 1982
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue J.J. Merlot(FAL) 35060 SambrevilleGround area
638 m²
Building footprint
82 m²
Parcel 92041A0075/00Z003, Wallonia. Linked by address, not a title deed.
2 establishment units
Rue J.J. Merlot(FAL) 23, 5060 Sambreville
since 19822.020.968.868
Rue de Fosses(FAL) 17, 5060 Sambreville
since 19822.020.968.967
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92041A0075/00Z003 | Wallonia | 638 m² | 1 · 82 m² | - |
Linked by address, not proof of ownership
Methodology
via establishment units: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
2 sitesSambreville2.020.968.868
Sambreville2.020.968.967
Similar companies · same sector, comparable size
MAUDENS JEROEN
BE 0884.829.347
Sint-Genesius-Rode · Eq €324,786
OSTEOSERV
BE 0870.735.346
Kinrooi · Eq €324,795
STEVENS PHARMA
BE 0442.284.960
Wezembeek-Oppem · Eq €324,659
PHARMACIE MARIE-ANNE LEFEBURE
BE 0827.755.141
Sint-Pieters-Woluwe · Eq €324,897
APOTHEEK DE LOORE ZWEVEZELE
BE 0898.945.619
Wingene · Eq €325,065
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,486 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded31-08-1982
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 43 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.